First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy …

S Han, YH Kim, HY Choi, DJ Soh, J Kim… - Drug Design …, 2020 - Taylor & Francis
Background Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor has therapeutic potential
for acute ischemic stroke by suppressing microglial activation and facilitating …
被引用次数：4 相关文章
[HTML] nih.gov

[HTML][HTML] First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in …

S Han, YH Kim, HY Choi, DJ Soh, J Kim… - Drug Design …, 2020 - ncbi.nlm.nih.gov
Background Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor has therapeutic potential
for acute ischemic stroke by suppressing microglial activation and facilitating …

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP-ribose) Polymerase-1 Inhibitor, JPI-289, in Healthy …

S Han, YH Kim, HY Choi, DJ Soh… - Drug design …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor has therapeutic potential
for acute ischemic stroke by suppressing microglial activation and facilitating …

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP-ribose) Polymerase-1 Inhibitor, JPI-289, in Healthy …

S Han, YH Kim, HY Choi, DJ Soh, J Kim… - Drug Design …, 2020 - go.gale.com
Background: Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor has therapeutic potential
for acute ischemic stroke by suppressing microglial activation and facilitating …

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy …

S Han, YH Kim, HY Choi, DJ Soh, J Kim… - Drug Design …, 2020 - dovepress.com
Background: Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor has therapeutic potential
for acute ischemic stroke by suppressing microglial activation and facilitating …

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP-ribose) Polymerase-1 Inhibitor, JPI-289, in Healthy …

S Han, YH Kim, HY Choi, DJ Soh, J Kim… - Drug Design …, 2020 - europepmc.org
Background Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor has therapeutic potential
for acute ischemic stroke by suppressing microglial activation and facilitating …